Related Experiment Video

Updated: May 22, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Platelet function and inhibition in ischemic heart disease

Annunziata Nusca1, Giuseppe Patti

  • 1Department of Cardiovascular Sciences, Campus Bio-Medico University of Rome, Via Alvaro del Portillo 200, Rome, Italy. a.nusca@unicampus.it

Current Cardiology Reports
|May 8, 2012
PubMed

Insights

Platelet inhibition is crucial for preventing thrombosis in acute coronary syndromes. New antiplatelet agents offer improved efficacy, addressing limitations of older drugs like clopidogrel.

Area of Science:

  • Cardiology
  • Hematology
  • Pharmacology

Background:

  • Platelets are central to thrombosis, a key factor in acute coronary syndromes and percutaneous coronary intervention complications.
  • Therapeutic strategies target platelet surface molecules, but low responsiveness to clopidogrel leads to recurrent ischemic events.
  • Genetic and environmental factors influence patient response to antiplatelet therapy.

Purpose of the Study:

  • To review the role of platelets in thrombosis and acute coronary syndromes.
  • To discuss the efficacy and limitations of clopidogrel and newer antiplatelet agents.
  • To explore novel therapeutic targets and adjunctive strategies in antiplatelet therapy.

Main Methods:

  • Literature review of studies on platelet function, thrombosis, and antiplatelet agents.
  • Analysis of clinical trial data for clopidogrel, prasugrel, ticagrelor, and cangrelor.
  • Examination of research on protease-activated receptor inhibitors.

Main Results:

  • Platelet aggregation involves multiple steps and surface molecules, making them targets for antiplatelet drugs.
  • Despite clopidogrel's demonstrated efficacy, low responsiveness remains a significant clinical challenge.
  • Newer P2Y12 inhibitors like prasugrel and ticagrelor show improved outcomes, while cangrelor offers rapid, reversible inhibition.
  • Protease-activated receptor inhibitors present a potential adjunctive therapy.

Conclusions:

  • Platelet inhibition is vital in managing acute coronary syndromes and PCI complications.
  • Advances in antiplatelet therapy, including new P2Y12 blockers, improve patient outcomes.
  • Addressing low drug responsiveness and exploring adjunctive therapies are key to optimizing treatment for coronary artery disease.

More Related Videos

Ferric Chloride-induced Murine Thrombosis Models10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro10:25

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro

Published on: March 19, 2016

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...